SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:portal.research.lu.se:publications/e310aaa5-7198-4819-8591-0c25ab1b7868"
 

Sökning: onr:"swepub:oai:portal.research.lu.se:publications/e310aaa5-7198-4819-8591-0c25ab1b7868" > Prostate cancer pol...

Prostate cancer polygenic risk score and prediction of lethal prostate cancer

Klein, Robert J. (författare)
Lund University,Icahn School of Medicine at Mount Sinai,Department of Genetics and Genomic Sciences and Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, NY, New York, United States,Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.;Icahn Sch Med Mt Sinai, Icahn Genom Inst, New York, NY 10029 USA.
Vertosick, Emily (författare)
Lund University,Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York, United States,Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA.
Sjoberg, Dan (författare)
Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York, United States,Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA.
visa fler...
Ulmert, David (författare)
Lund University,University of California, Los Angeles,University of California, Los Angeles,University of California, Los Angeles,University of California, Los Angeles,Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.;David Geffen UCLA Sch Med, Ahmanson Translat Imaging Div, Los Angeles, CA USA.;David Geffen UCLA Sch Med Los, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA.;Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA.;Univ Calif Los Angeles, Inst Urol Oncol, Los Angeles, CA USA.
Rönn, Ann Charlotte (författare)
Karolinska University Hospital,Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden,Karolinska Univ Hosp, Clin Res Ctr, Huddinge, Sweden.
Häggström, Christel (författare)
Umeå universitet,Lund University,Umeå University,Uppsala University,Uppsala universitet,Enheten för biobanksforskning,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden,Endokrinkirurgi,Umeå Univ, Dept Biobank Res, Umeå, Sweden.
Thysell, Elin (författare)
Umeå universitet,Patologi,Umeå University,Umeå Univ, Dept Med Biosci, Umeå, Sweden.
Hallmans, Göran, 1947- (författare)
Umeå universitet,Avdelningen för hållbar hälsa,Umeå University,Umeå Univ, Dept Publ Hlth & Clin Med, Umeå, Sweden.
Dahlin, Anders (författare)
Internal Medicine - Epidemiology,EpiHealth: Epidemiology for Health,Internmedicin - epidemiologi,Department of Clinical Sciences, Lund University, Malmö, Sweden,Lund Univ, Dept Clin Sci, Malmö, Sweden.
Stattin, Pär (författare)
Uppsala universitet,Urologkirurgi
Melander, Olle (författare)
MultiPark: Multidisciplinary research focused on Parkinson´s disease,EXODIAB: Excellence of Diabetes Research in Sweden,EpiHealth: Epidemiology for Health,Cardiovascular Research - Hypertension,Kardiovaskulär forskning - hypertoni,Department of Clinical Sciences, Lund University, Malmö, Sweden; Department of Emergency and Internal Medicine, Skåne University Hospital, Malmö, Sweden,Skåne University Hospital,Lund Univ, Dept Clin Sci, Malmö, Sweden.;Skane Univ Hosp, Dept Emergency & Internal Med, Malmö, Sweden.
Vickers, Andrew (författare)
Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York, United States,Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA.
Lilja, Hans (författare)
EpiHealth: Epidemiology for Health,LUCC: Lund University Cancer Centre,LUCC: Lunds universitets cancercentrum,Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, NY, New York, United States; Department of Translational Medicine, Lund University, Malmö, Sweden,Memorial Sloan-Kettering Cancer Center,Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA.;Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.;Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.;Lund Univ, Dept Translat Med, Malmö, Sweden.
visa färre...
 (creator_code:org_t)
2022-04-08
2022
Engelska.
Ingår i: NPJ precision oncology. - : Springer Nature. - 2397-768X. ; 6:1
Relaterad länk:
https://doi.org/10.1... (free)
visa fler...
https://umu.diva-por... (primary) (Raw object)
https://uu.diva-port... (primary) (Raw object)
https://doi.org/10.1...
https://urn.kb.se/re...
https://urn.kb.se/re...
http://kipublication...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Polygenic risk scores (PRS) for prostate cancer incidence have been proposed to optimize prostate cancer screening. Prediction of lethal prostate cancer is key to any stratified screening program to avoid excessive overdiagnosis. Herein, PRS for incident prostate cancer was evaluated in two population-based cohorts of unscreened middle-aged men linked to cancer and death registries: the Västerbotten Intervention Project (VIP) and the Malmö Diet and Cancer study (MDC). SNP genotypes were measured by genome-wide SNP genotyping by array followed by imputation or genotyping of selected SNPs using mass spectrometry. The ability of PRS to predict lethal prostate cancer was compared to PSA and a commercialized pre-specified model based on four kallikrein markers. The PRS was associated with incident prostate cancer, replicating previously reported relative risks, and was also associated with prostate cancer death. However, unlike PSA, the PRS did not show stronger association with lethal disease: the hazard ratio for prostate cancer incidence vs. prostate cancer metastasis and death was 1.69 vs. 1.65 in VIP and 1.25 vs. 1.25 in MDC. PSA was a much stronger predictor of prostate cancer metastasis or death with an area-under-the-curve of 0.78 versus 0.63 for the PRS. Importantly, addition of PRS to PSA did not contribute additional risk stratification for lethal prostate cancer. We have shown that a PRS that predicts prostate cancer incidence does not have utility above and beyond that of PSA measured at baseline when applied to the clinically relevant endpoint of prostate cancer death. These findings have implications for public health policies for delivery of prostate cancer screening. Focusing polygenic risk scores on clinically significant endpoints such as prostate cancer metastasis or death would likely improve clinical utility.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst. Hantera kakor

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy